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Abstract
Purpose—Our purpose was to characterize the clinical influences, genetic risk factors, and gene 
mechanisms contributing to persistent cisplatin-induced peripheral neuropathy (CisIPN) in 
testicular cancer survivors (TCS).
Experimental Design—TCS given cisplatin-based therapy completed the validated EORTC 
QLQ-CIPN20 questionnaire. An ordinal CisIPN phenotype was derived and associations with age, 
smoking, excess drinking, hypertension, body mass index, diabetes, hypercholesterolemia, 
cumulative cisplatin dose, and self-reported health were examined for 680 TCS. Genotyping was 
performed on the Illumina HumanOmniExpressExome chip. Following quality control and 
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imputation, 5.1 million SNPs in 680 genetically European TCS formed the input set. GWAS and 
PrediXcan were used to identify genetic variation and genetically-determined gene expression 
traits, respectively, contributing to CisIPN. We evaluated two independent datasets for replication: 
Vanderbilt’s electronic health database, BioVU and CALGB 90401 trial.
Results—Eight sensory items formed a subscale with good internal consistency (Cronbach 
α=0.88). Variables significantly associated with CisIPN included age at diagnosis (OR per 
year=1.06, p=2 × 10−9), smoking (OR=1.54, p=0.004), excess drinking (OR=1.83, p=0.007), and 
hypertension (OR=1.61, p=0.03). CisIPN was correlated with lower self-reported health 
(OR=0.56; p=2.6 × 10−9) and weight gain adjusted for years since treatment (OR per Δkg/
m2=1.05, p=0.004). PrediXcan identified lower expressions of MIDN and RPRD1B, and higher 
THEM5 expression as associated with CisIPN (p-value for each < 5 × 10−6) with replication of 
RPRD1B meeting significance criteria (Fisher’s combined p=0.0089).
Conclusions—CisIPN is associated with age, modifiable risk factors and genetically-determined 
expression level of RPRD1B. Further study of implicated genes could elucidate the 
pathophysiologic underpinnings of CisIPN.
Keywords
cisplatin; peripheral neuropathy; genome wide association study; cancer survivorship; Platinum 
Study; young adult; testicular cancer; germ cell tumor; patient reported outcomes; 
pharmacogenetics
INTRODUCTION
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most common and often 
debilitating adverse effects of modern chemotherapy (1, 2). Platinum analogs, taxanes, vinca 
alkaloids, thalidomide, and epothilones are associated with CIPN, although with different 
clinical manifestations, which include sensory, motor and autonomic symptoms (1). 
Mechanisms underlying CIPN remain largely unclear (2). Unlike taxane-related CIPN, 
which can be reversible (2), cisplatin-induced peripheral neuropathy (CisIPN) can be 
cumulative and progressive and cause long-term effects on overall quality of life (QoL) and 
physical function (3). Studies have suggested that age, race, diabetes and obesity may be risk 
factors for CIPN (4, 5), but results have been conflicting (6–11).
No agents are currently available to prevent or treat CIPN (12). Management of CIPN is 
complicated by the lack of reliable means to identify at-risk patients. While genetic variants 
could address unexplained phenotypic variability, heterogeneity of treatment regimens and 
the lack of long-term patient follow-up complicate pharmacogenetic studies of 
chemotherapeutic toxicities, including CIPN. However, cisplatin-based chemotherapy for 
testicular cancer is relatively homogeneous, and is curative (13). Testicular cancer survivors 
(TCS) are typically young at diagnosis, and the period of survivorship can span upwards of 
50 years, providing an ideal model to investigate long-term adverse effects of cisplatin-based 
chemotherapy. These include hearing impairment, tinnitus, renal dysfunction, cardiovascular 
disease, secondary malignancies, CisIPN, and others (14). CisIPN most commonly presents 
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as a sensory neuropathy in a stocking-glove distribution with numbness, tingling, 
paresthesias, loss of proprioception, hyperalgesia and/or allodynia (3).
Although cisplatin is one of the most widely prescribed chemotherapeutics, there are few 
data available on genetic variants associated with CisIPN. Prior investigations assessed 
variants in a few candidate genes in small numbers of patients (range 104–238), who often 
also received other neurotoxic agents (15–18). In this study, we used the extensively 
validated EORTC-CIPN20 scale (19) and other patient-reported outcomes (PRO) to 
characterize CisIPN in a large number of TCS, the impact on self-reported health, and 
associated clinical and demographic variables. We additionally conducted, to our 
knowledge, the first genome-wide association study of CisIPN.
PATIENTS AND METHODS
Patients
All patients were enrolled in The Platinum Study, a cross sectional study that includes 8 
cancer centers in the United States and Canada (14). Eligibility criteria included: men 
diagnosed with a histologically or serologically confirmed germ cell tumor (GCT), age <55 
years at diagnosis and >18 years at enrollment, treatment with cisplatin-based chemotherapy 
for either initial GCT or recurrence, no antecedent chemotherapy for another primary cancer 
and no subsequent salvage chemotherapy. Of all eligible patients, 93% agreed to participate. 
Study procedures were approved by the Human Subjects Review Board at each institution. 
All patients provided written consent for participation in study procedures, including genetic 
analyses.
Data Collection
TCS visiting the clinic for follow-up and who provided written consent for participation 
underwent a brief physical examination, including measurement of height and weight. Body 
mass index (BMI) (kg/m2) was defined as normal, overweight, obese, or morbidly obese 
(<25, 25 to <30, 30 to <40, and ≥40 kg/m2, respectively). Figure S1 illustrates the data 
collection pipeline. Patients completed questionnaires with regard to neurotoxic symptoms, 
comorbidities, lifestyle behaviors, perceived health and medication use at the time of 
enrollment (range: 1–30 years after treatment completion). These included the EORTC-
QLQ-CIPN20 questionnaire with questions listed in Table S1 (20). Data abstracted from 
medical records with standardized forms included all variables related to GCT diagnosis and 
treatment. For each administered cytotoxic drug, information was collected on name, dose, 
date(s) of administration, number of cycles, and cumulative dose.
Phenotype Analysis
We evaluated the frequency of sensory neuropathy using 9 items in the EORTC-CIPN20 
(19). We assessed inter-item associations as well as relationships with motor and autonomic 
neuropathy by variance analysis using principal component analysis (PCA), following 
conversion of the Likert scale to a 0–3 numeric scale: 0 for “none”, 1 for “a little”, 2 for 
“quite a bit”, 3 for “very much”. We evaluated subscale internal consistency using Cronbach 
α (21). Following exclusion of the hearing impairment item, we created a summary statistic 
Dolan et al. Page 3
Clin Cancer Res. Author manuscript; available in PMC 2018 October 01.
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
A
uthor M
anuscript
of CisIPN mathematically equivalent to the standard scoring algorithm (22): rather than 
summing item scores and scaling to 0–100, we took the mean of the scores, effectively 
summing scores and scaling to 0–3 and imputing missing data points from available ones 
(11 samples were missing one response, and two samples were missing three responses). 
The ceiling function was then used to place means into four ordinal groups reflecting the 
average severity across symptoms created as follows: none (0; mean = 0), a little (1; 0 < 
mean ≤ 1), quite a bit (2; 1 < mean ≤ 2), very much (3; 2 < mean ≤ 3). Groups 2 and 3 were 
combined due to low frequency.
Ordinal Regressions with Relevant Variables
We determined the statistical association between CisIPN and data abstracted from the 
medical records at the time of treatment and data collected at the time of clinical evaluation. 
Dependent variables abstracted from the medical records included GCT treatment regimen, 
cumulative cisplatin dose, age and BMI at the initiation of treatment. Data collected at 
clinical evaluation included age and BMI, self-reported smoking status, alcohol 
consumption, blood pressure, diabetes, and hypercholesterolemia. Age was analyzed as a 
continuous variable. Ever smokers were defined as those responding affirmatively to “have 
you ever smoked?”. Excessive drinkers were defined as those who reported consuming ≥ 2 
drinks/day on average in the past year. Hypertensive patients were those who both indicated 
that they had received a diagnosis of high blood pressure and were taking prescription 
medication for it at the time of evaluation. Diabetic patients were those who indicated they 
had 1) diabetes requiring insulin or 2) diabetes requiring tablets or pills. We also took into 
consideration those patients currently taking prescription medication for high cholesterol in 
view of the small risk of neuropathy associated with statin therapy (23). TCS were also 
asked to rate their health as “excellent,” “very good,” “good,” “fair,” or “poor”, and to report 
the average time per week engaged in various physical activities during the past year (24). 
Total kilocalories per week were estimated by summing Metabolic Equivalent of Task 
(MET)-hours for each physical activity and multiplying by the participant’s weight 
(kilograms). Kilocalories per week were calculated and categorized as vigorous (≥6 METs), 
moderate (3 to <6 METs), and less than moderate (<3 METs) physical activity (25). Weight 
gain was determined as the difference in BMI between initiation of chemotherapy and study 
evaluation (Δkg/m2). Association with the CisIPN phenotype was evaluated in proportional 
odds ordered logistic regression models at α = 0.05. All univariate regressions were adjusted 
for age at diagnosis (covariate). A multi-variable regression model was constructed by using 
all significant variables in the age-adjusted univariate analysis.
Genotyping and Imputation
DNA extraction was performed from peripheral blood. SNPs were genotyped on the 
Illumina HumanOmniExpressExome chip (Illumina, San Diego, CA) at the RIKEN Center 
for Integrative Medical Science (Yokohama, Japan). Figure S2 illustrates the CONSORT 
flow diagram for the TCS. Quality control (QC) was performed as previously described (26). 
Individuals with pairwise identity by descent (IBD) > 0.125 and excess heterozygosity (F 
inbreeding coefficient >6 standard deviations from the mean) were excluded, leaving 827 
individuals. PCA was performed on the genotype data to quantify genomic ancestry using 
SMARTPCA (27), revealing 713 genetically European individuals. Out of those, 680 had 
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complete phenotypic data (CIPN20, cisplatin dose, demographics), and composed the study 
sample. SNPs with call rate < 0.99 and Hardy-Weinberg equilibrium (HWE) P < 1×10−6 
were excluded, leaving 930,450 SNPs. These comprised the input set of genotype 
imputation with SHAPEIT phasing, which we performed on the University of Michigan 
Imputation Server using the EUR (European) population in 1000G Phase 1v3 ShapeIt2 (no 
singletons) reference panel (28). 5,068,489 SNPs with minor allele frequency (MAF) > 0.05, 
imputation R2 > 0.8 and INFO score 0.6–1.05 were retained for further analysis. No genetic 
PC was associated with CisIPN in univariate or multivariate analyses investigating the first 
10 PCs.
Independent SNP Analysis
We performed independent SNP association tests with CisIPN by proportional odds ordinal 
logistic regression adjusted for covariates and assuming linear additive SNP effects. These 
did not include heritable covariates significantly associated with CisIPN, because they can 
bias effect estimates (29). R version 3.2.0 was used.
GCTA and PrediXcan Analysis
We estimated narrow-sense heritability using a variance-component model with a genetic 
relationship matrix (GRM) estimated from genotypes using GCTA (30). SNPs with HWE P 
> 0.05 and MAF > 0.05 and one of a pair of individuals with estimated relatedness >0.025 
were included, leaving 4,897,434 SNPs and 623 individuals. We performed gene-based 
associations using PrediXcan (31). Briefly, PrediXcan uses reference transcriptome data to 
generate models ‘imputing’ gene expression in patients from their genotype data by 
leveraging the effects of SNPs predicting expression. In this study, we used models derived 
from the application of elastic net (α = 0.5). Genome-wide expression was predicted using 
reference transcriptome panels in four candidate tissues, chosen for their representation of 
the nervous system and the microenvironment of peripheral nerves and endings: whole blood 
using Depression Genes and Networks (DGN) (32), and three tissues from GTEx (33): tibial 
nerve, skin (not exposed to sun), and cerebral cortex. DGN (instead of GTEx) was used as a 
reference set for whole blood due to the larger sample size (n = 922 vs. 338). Genes with 
prediction R2 > 0.01 and prediction p < 0.05 were included. Genes with low-variance 
predicted expression were excluded (σ2 < 0.001). Associations were obtained by ordinal 
regression as described, with predicted expression as the independent variable and age as a 
covariate. Genome-wide significance was set at α = 0.05 with Bonferroni correction for the 
number of genes tested within the tissue. Experiment-wide significance was set 
conservatively with Bonferroni correction for the total number of tests performed in all four 
tissues.
Replication
To replicate our findings, we used two additional independent datasets, Vanderbilt’s 
electronic health records (EHR) BioVU (34, 35) and the CALGB 90401 trial (36). The 
BioVu cohort was composed of 18,620 genotyped individuals that were linked to EHR (34) 
and given a PheWAS code (ICD9-derived codes) for polyneuropathy due to drugs (n=20, 
ICD-9 code 316.1). Association with predicted gene expression was evaluated by one-tailed 
logistic regression in the direction of the discovery. For CALGB 90401, pre-imputation 
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genotype quality control was performed with 543,834 SNPs and 623 genetically European 
individuals as described (36). Genotypes were imputed using IMPUTE2 software and the 
1000 Genomes phase 3 EUR reference population. 3,031,145 SNPs with MAF > 0.05, 
IMPUTE2 INFO score > 0.3 were retained for further analysis. We evaluated the association 
of predicted gene expression with cumulative docetaxel dose (adjusted for competing-risks) 
at the time of occurrence of grade 3 or higher neuropathy using one-tailed Cox proportional 
hazards regression (36). Replication significance was assessed with Fisher’s combined p-
value method using the one-tailed p-values of the two independent replications at α = 0.05.
RESULTS
Cohort Characteristics
The clinical and demographic characteristics of the genetically European subjects (n = 680) 
that passed all QC and had full phenotypic data are shown in Table 1 (additional diagnosis 
and treatment characteristic are listed in Table S2). Median age at testicular cancer diagnosis 
was 31 years (range: 15–50) with a median of 4.8 years (range: 0.4–30) between treatment 
completion and clinical evaluation. Chemotherapy regimens consisted largely of bleomycin, 
etoposide, and cisplatin (62.9%) or etoposide and cisplatin (29.9%). At the time of 
enrollment, one in three patients (33.6%) were either obese (BMI: 30 to 39) or morbidly 
obese (BMI ≥40) and only 16.8% participants reported having excellent health (Table S2 
and Table 1). Current use of prescription medications for hypertension, 
hypercholesterolemia, and diabetes was reported by 12.8%, 11.0%, and 3.1% of participants, 
respectively. Approximately 42% of patients are former (34.4%) or current smokers (7.5%). 
For those, the median number of years smoking is 5, and the mean is 8.6.
Phenotype Analysis
The EORTC-CIPN20 scale questionnaire (20) included nine sensory, eight motor and three 
autonomic items (Table S1). More than one third (36–38%) of patients reported 
experiencing some degree of tingling or numbness in hands and/or feet within the four 
weeks preceding clinical evaluation, with a smaller proportion (8–14%) reporting shooting 
pain, difficulty distinguishing hot and cold water, and problems feeling the ground (Figure 
S3). PCA indicated that items generally clustered by symptom type on the first two Principal 
Components (PCs), except for hearing loss (Figure S4). In the third and fourth PC, sensory 
and motor items clustered by limb (i.e., fingers/hands vs. toes/feet). Cumulatively, the four 
PCs explained 60% of the total phenotypic variance. Autonomic items and the hearing loss 
item formed a distinct cluster on both plots. We have previously comprehensively evaluated 
hearing loss in this cohort with quantitative audiometry (37) and assessed genetic variants 
associated with cisplatin-induced ototoxicity (26). Therefore, we excluded hearing loss item 
from the sensory subscale. The eight remaining items indicated high levels of internal 
consistency (Cronbach α = 0.88). We created a summary statistic of CisIPN using those 
items as described. Overall, more than half (56.2%) of patients reported at least some degree 
of sensory neuropathy, while motor symptoms were less common overall with 45.2% 
experiencing some form of motor neuropathy and 2.8% with quite a bit/very much (Figure 
1) consistent with the observation that cisplatin predominantly causes sensory neuropathy 
(3).
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CisIPN Association with Diagnosis and Treatment Characteristics
Summaries of statistical associations between evaluated variables and CisIPN are presented 
in Table 2A. CisIPN was associated with age at diagnosis (OR = 1.06, p = 2 × 10−9). BMI at 
evaluation did not correlate with CisIPN. Type of chemotherapy regimen (EP vs. BEP [data 
not shown]) and cumulative cisplatin dose (range: 100–800 mg/m2) were not significantly 
associated with CisIPN. Importantly, the number of years since therapy did not correlate 
negatively with CisIPN (p = 0.43) in age-adjusted analyses, suggesting there is no 
attenuation of symptoms over time several years following chemotherapy (data not shown). 
A longitudinal study or one with baseline data remains more appropriate to assess symptom 
progression.
CisIPN Association with Clinical and Behavioral Characteristics at Evaluation
Age at evaluation significantly correlated with CisIPN (OR = 1.04, p = 2 × 10−8) but 
displayed a slightly smaller effect size than at diagnosis (Table 2B). Age at diagnosis and 
evaluation were highly correlated (R2 = 0.8), and therefore, subsequent analyses were 
adjusted for age at diagnosis only. Smoking status (‘ever smoker’) (OR = 1.54; p= 0.004) as 
well as the self-reported number of years smoking (OR = 1.04 per year, p = 0.0002 [data not 
shown]) and excess drinking (OR = 1.83; p = 0.007) were significantly associated with 
CisIPN in univariate, age-adjusted analyses. CisIPN was also negatively correlated with 
physical activity level (OR = 0.72; p = 0.02; data not shown). Hypertension displayed a 
correlation (OR = 1.61, p = 0.03) with CisIPN, but not hypercholesterolemia (OR = 0.92, p 
= 0.72) or diabetes (OR = 1.27, p = 0.59), although the sample size of the latter was small 
(n=21). In the multivariate model, hypertension was marginally associated with CisIPN 
while age, smoking status, and excessive drinking displayed consistent effect sizes and 
statistical significance (Table 2C). BMI at evaluation was marginally associated with CisIPN 
(OR = 1.03, p = 0.051). Weight gain as measured by the absolute difference in BMI at 
evaluation and BMI at treatment initiation showed a stronger and more significant 
association with CisIPN (OR per Δkg/m2= 1.05; p = 0.004, adjusted for years since 
treatment, Figure 2A).
CisIPN Association with Self-Reported Health
In a univariate analysis, we found a strong negative correlation of CisIPN with self-reported 
health (OR = 0.56; p = 2.6 × 10−9) (Figure 2B). A multivariate model with self-reported 
health as the dependent variable revealed a negative correlation with CisIPN (OR = 0.59, p < 
0.0001) and with weight gain since treatment (OR = 0.91, p < 0.0001), and a positive 
correlation with physical activity (25) (OR = 1.92, p < 0.0001). Considering additional 
variables, self-reported health negatively associated with smoking (OR = 0.64, p= 0.003) but 
not hypertension (OR = 0.69, p = 0.096) or excess drinking (OR = 0.70, p = 0.12). CisIPN 
(OR = 0.64, p < 0.0001), weight gain (OR per Δkg/m2= 0.91, p < 0.0001), and exercise (OR 
= 1.97, p < 0.0001) remained the most significantly associated variables in a model 
including hypertension and smoking. We compared these findings in CisIPN to ototoxicity 
on the subset of TCS (n = 511) with quantitative audiometry included in a prior report (37), 
using a rank normalized geometric mean of audiogram thresholds in linear regression, 
adjusted for age. Although cisplatin-associated hearing loss and CisIPN were correlated (β = 
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0.14, p = 0.008), there was no relationship between ototoxicity and weight gain, physical 
activity, or self-reported health (data not shown, p > 0.05).
GWAS of CisIPN
The results of the GWAS using the 5,068,489 SNPs with age as a covariate are shown in 
Figure S5, and the top 100 SNPs in Table S3. No SNP met genome-wide significance (p < 5 
× 10−8). None of the four SNPs in GSTP1 (18, 38), ABCG2 (39), XPC (39), and ERCC1 
(15) previously identified in candidate gene studies of peripheral neuropathy following 
platinum-based regimens were replicated (Table S4). Out of the four SNPs meeting genome-
wide significance in previous GWAS of CIPN due to other neurotoxic chemotherapies 
(Table S5), one SNP (rs7349683 in EPHA5) met replication significance (p = 0.05) with a 
concordant direction of effect. A SNP in ATP8A2 (rs1326116) that was of borderline 
significance (p=1.8 × 10−6) in a GWAS of docetaxel-induced neuropathy (36) showed the 
same direction of effect and met replication significance (p= 0.01).
GCTA and PrediXcan Analysis
Using GCTA (30), we found CisIPN to be highly heritable, with common variants 
explaining up to 74% of phenotypic variability (h2 = 0.74, SE = 0.48; p = 0.03). This finding 
suggests a polygenic architecture of CisIPN. We used PrediXcan, a gene based test (31), to 
associate genetically regulated components of gene expression with CisIPN (Figure 3). This 
method increases power to explain the heritability by aggregating the effects of SNPs 
associated with gene expression. The most significant (p <0.001) results are listed in Table 
S6. One gene met experiment-wide significance (MIDN in skin, p = 1.4 × 10−6) and two 
genes met genome-wide significance (RPRD1B in whole blood, p = 3.4 × 10−6 and THEM5 
in tibial nerve, p = 4.9 × 10−6). RPRD1B revealed a protective effect, i.e. lower RPRD1B 
gene expression is associated with CisIPN (Figure 4A). MIDN had the same direction of 
effect, while THEM5 displayed the opposite. Although RPRD1B was discovered using 
DGN, it was the second most significant hit in both GTEx skin and tibial nerve tissues.
In efforts to replicate, we interrogated a BioVu cohort of 18,620 genotyped individuals that 
were linked to EHR (34, 35) with the phenotype “polyneuropathy due to drugs” and found 
lower PrediXcan-predicted RPRD1B expression was associated with this phenotype (Figure 
4B, one-tailed p = 0.021, 20 cases, 18600 controls). We further investigated the association 
in the Cancer and Leukemia Group B (CALGB) 90401 cohort, an independent dataset 
assessing docetaxel-induced peripheral neuropathy and found it nominally significant 
(Figure 4C, HR = 0.4, one-tailed p = 0.055). We assessed replication significance by 
computing the combined p-value using Fisher’s method and found replication to be 
significant (p = 0.0089).
DISCUSSION
Although cisplatin is one of the most commonly used cytotoxic drugs worldwide, to our 
knowledge, this study represents the first and largest investigation comprehensively 
evaluating clinical and genome-wide associations with long-term CisIPN in TCS, an ideal 
population for long-term pharmacogenetic studies of cisplatin toxicities. The validated 
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EORTC-CIPN20 was applied in this large series to capture a broad spectrum of neurological 
damage from the patient’s perspective that might not be apparent on formal neurologic 
testing (40), and confounded by interpretation in physician-graded scales (41). We found 
sensory CisIPN symptoms to be common, and significantly correlated with weight gain 
since treatment, and inversely correlated with self-reported health and physical activity. In 
univariate models, we identified age, smoking status, excess drinking, and hypertension as 
significantly associated with CisIPN. As these variables are non-independent, we assessed 
their associations in a multivariate model and found some of the effect of hypertension to be 
explained by the other variables. The cross-sectional design prevents conclusions as to 
whether these associated variables are risk factors or consequences of CisIPN which would 
require a prospective design. We found significant heritability, indicating that genetic 
variants could explain a large proportion of variability in the phenotype. Aggregating SNP 
effects using PrediXcan (31), a gene-level test imputing genetically regulated expression 
from genotypes, revealed lower expression of MIDN in skin and RPRD1B in whole blood, 
as well as higher expression of THEM5 in tibial nerve as genome-wide significant. Using 
two independent datasets, we replicated the finding that lower RPRD1B predicted 
expression is associated with drug-induced neuropathy using predictors from whole blood, 
investigating a docetaxel-induced neuropathy phenotype and a broader drug-induced 
polyneuropathy phenotype in EHR.
PrediXcan
PrediXcan is a recently developed gene-based method that tests the genetically determined 
component of gene expression in a given tissue for association with a phenotype (31). The 
use of genetically determined gene expression to identify trait-associated genes is supported 
by evidence that SNPs associated with chemotherapeutic drug susceptibility (42) and 
complex traits (43) are more likely to be sites that associate with gene expression. Further, 
an observed association with the genetic component proposes a causal direction of effect 
since the phenotype does not alter the germline genetic profile. We theorized that tibial 
nerve, skin, and whole blood best represent neuronal tissue and the microenvironment 
surrounding nerves and their endings, a potentially important source of variability in CIPN. 
Since genetic regulation of gene expression can be non-tissue specific, the Bonferroni 
correction (correcting for the total number of tests across the tissues) is conservative. In 
three of the four tissues tested, lower expression of RPRD1B is associated with CisIPN at p 
< 10−4, illustrating substantial tissue-shared genetic regulation. Vanderbilt’s BioVU 
identified lower predicted gene expression of RPRD1B in the discovery tissue (DGN whole 
blood) as associated with drug-induced polyneuropathy. However, the analysis could not 
distinguish drug classes. Further suggestive association of neuropathy with lower expression 
of RPRD1B in the CALGB 90401 may indicate that the mechanism for the association is not 
drug-specific, as that trial investigated neuropathy induced by docetaxel, another neurotoxic 
chemotherapeutic agent with a distinct mechanism of cytotoxicity. Therefore, RPRD1B 
might have broad implications in CIPN.
RPRD1B
Twenty SNPs in four distinct linkage disequilibrium blocks (R2 < 0.5) 36–37.5 kilobases 
into chromosome 20 predict RPRD1B expression. RPRD1B codes for Kub5-Hera, a protein 
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regulating the binding of RNA polymerase II to CCND1 gene (cyclin D1), and regulating 
the transcription of several genes involved in the cell cycle (44). Emerging data indicate that 
RPRD1B plays an important role in several DNA repair mechanisms, including double-
strand breaks (DSB) repair through the association with core non-homologous end joining 
(NHEJ) proteins (45) and mismatch repair (46). Defects in RPRD1B expression or 
knockdown cause a deficiency in DNA repair mechanisms known to be critical in resolving 
cisplatin-induced lesions (47). Consistent with our data indicating low levels of RPRD1B 
being associated with CisIPN, knockdown of this gene in a breast cancer cell line, MDA-123 
results in increased sensitivity to cisplatin (45). However, the suggestive association of 
RPRD1B with docetaxel-induced neuropathy, indicates that other mechanisms may be 
important. RPRD1B functions as a co-activator of the β-catenin-TCF complex to enhance 
the transcriptional activity of Wnt signaling (48). Wnt signaling is critical for initial neural 
cell-fate determination, patterning and synapse formation of sensory neurons of the dorsal 
root ganglia. This signaling pathway is also active in adult sensory neurons and modulates 
sensitivity to nociceptive stimuli (49, 50). Mechanistic insights into the function of RPRD1B 
are warranted to assess its role in the pathophysiology of neurotoxicity, possibly revealing 
novel targets.
Demographic and clinical factors and health behaviors
Our study identified age, smoking, excess alcohol use, and hypertension as associated with 
CisIPN. The relationship with age is consistent with several previous reports of taxane-
induced neuropathy, including ECOG 5103 (4, 8, 36). In contrast, a number of studies of 
oxaliplatin-treated patients did not find an association with age (6, 7).
Tobacco and alcohol use—Few studies have addressed the role of tobacco use in CIPN. 
The authors of one study that found a correlation between smoking and CIPN postulated that 
long-term heavy smoking reduces peripheral blood flow, likely exacerbating paclitaxel-
induced neuropathy (5). Conversely, a study of 730 TCS given platinum-based 
chemotherapy (9) and another of 62 colon cancer patients receiving oxaliplatin reported no 
association (7). Among 169 patients given oxaliplatin-based chemotherapy, alcohol 
consumption was associated with neuropathy (6). In contrast, two studies in breast cancer 
patients found no such relation of CIPN (10, 11). Alcohol-related peripheral neuropathy is a 
complication of alcoholism affecting up to half of these individuals (51). Excess alcohol use 
also plays a role in the development and progression of diabetic neuropathy (52).
Hypertension—In our study, the association between hypertension and CIPN was of 
borderline significance in multivariate analyses. Hypertension was not significantly 
associated with CIPN in the studies by Hershman et al. (4) and Glendenning et al. (9). One 
could postulate that microvascular complications associated with hypertension may 
contribute to CIPN, but our findings remain to be confirmed in other studies.
Lower physical activity and weight gain—We found CisIPN was associated with 
lower physical activity levels and greater weight gain since chemotherapy completion. While 
a longitudinal study design would be best for establishing causal inferences, it is possible 
that CIPN symptoms could deter from physical activity and thereby promote weight gain. 
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Known downstream effects of weight gain include obesity, diabetes and other medical 
complications. Another long-term study in TCS has shown other co-morbidities are 
associated with CIPN, including neuroticism (53), further emphasizing the clinical impact of 
CIPN symptoms and their effects on patient health.
Strengths and limitations
A major strength of our study consists of its comprehensive assessment of a variety of 
clinical and genetic factors associated with CisIPN. Other strengths include the homogeneity 
of cisplatin-based chemotherapy without the administration of other neurotoxic drugs, 
detailed data on cisplatin dose, and the high patient participation rate (93%). Patient reported 
outcomes were carefully considered, and for the CisIPN phenotype, the validated EORTC 
QLQ-CIPN20 questionnaire (20) was applied. Although a number of studies of CIPN 
(reviewed above) considered the influence of one or a few covariates on CIPN, the present 
investigation considered all variables taken together. In addition, to our knowledge, no other 
study has considered the impact of CIPN on self-reported health or reported associations 
with weight gain and physical activity. PrediXcan (31), a state-of-the-art gene based method 
implicated RPRD1B, a gene known to play an important role in DNA repair mechanisms 
involved in cisplatin-induced damage, and shown to increase cisplatin sensitivity upon 
knockdown (45). Predictions are most helpful for variables known prior to treatment, yet as 
in previous studies (15, 18, 38, 39), baseline data before treatment were not collected. Any 
cross-sectional study design has potential inherent limitations, and does not allow us to infer 
causation of other evaluated risk factors for CisIPN, but rather to report important 
associations.
Another limitation in this study is the underpowered statistical analyses, as only 85 out of 
680 reported severe CisIPN, although a larger proportion reported moderate symptoms (297 
of 680). A larger sample size would allow better estimation of the effects of clinical factors 
and SNPs, and would enable making meaningful inferences about phenotype heritability 
which is limited by large standard errors here. Last, in replicating our study in a large set of 
EHR, we found lower predicted gene expression of RPRD1B to be associated with drug-
induced polyneuropathy; however this phenotype was not able to distinguish specific drug 
classes.
Conclusions
In view of the significant associations we found between smoking, excess alcohol use, 
decreased physical activity, and weight gain with CisIPN, health care providers should 
promote a healthy lifestyle among patients with CisIPN. The borderline significant 
association we observed for hypertension and CisIPN remains to be confirmed in other 
studies, but nonetheless, in view of the highly significant relationship we previously reported 
between hypertension and hearing loss in TCS (37), health care providers should carefully 
monitor blood pressure.
There are currently no agents available to prevent or treat CIPN (12), which in our 
population and as reported by others (9) persists long-term for cisplatin. This observation 
underscores the importance of identifying at-risk patients prior to the administration of 
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chemotherapy, which is currently not possible. Significant heritability indicates that a large 
proportion of variability in toxicity could be explained by genetic variants, but larger 
samples are needed to reduce the standard error before variants can be used in clinical 
prediction. Future research efforts should continue to elucidate the genetic underpinnings of 
CIPN, with our investigation now showing the importance of using functional genomic 
information such as expression data in genome-wide analyses to improve power and provide 
mechanistic explanations. Such approaches are more robust than reporting single 
polymorphisms with small-to-moderate effect sizes, which require larger datasets and are 
less clinically impactful. In addition, future research efforts should continue to provide the 
underpinnings for the eventual development of risk prediction models for CIPN that take 
into account not only genetic influences, but also clinical, demographic, and other important 
covariates. Our study provides one such example of a comprehensive approach. Future 
efforts will focus on independent replication in a similarly characterized TCS cohort, and 
evaluation of the predictive power of the variables associated in this study to potentially 
translate models of CisIPN prediction into the clinic.
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EORTC QLQ-CIPN20 European Organisation for Research and Treatment of 
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PCA principal component analysis
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Translational Relevance
Cisplatin is one of the most commonly prescribed chemotherapeutics worldwide, but is 
associated with multiple toxicities that adversely impact survivors’ quality of life. One 
such toxicity, CisIPN often persists and can be debilitating. We identified strong effects 
of long-term CisIPN on self-reported health and showed associations of CisIPN with age, 
hypertension and modifiable risk factors such as smoking, excess drinking and weight 
gain since treatment. We found CisIPN to be highly heritable, indicating that genetic 
variants could explain phenotypic variability. We implicated lower (genetically 
determined) expression of RPRD1B and MIDN and higher expression of THEM5 as 
associated with CisIPN. RPRD1B was replicated in an independent cohort of patients 
who developed drug-induced polyneuropathy and was of borderline significance in a 
clinical trial of docetaxel-induced neuropathy. RPRD1B functions in DNA repair, 
transcription, and cell cycle control and may be a target for drug development. Our data 
indicate the importance of both clinical characteristics and genetic variation in the 
development of long-term CisIPN.
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Figure 1. Distributions of summary statistics for A) the sensory subscale (eight items), and B) the 
motor items (eight items)
Outset: Following the conversion of the Likert “none”-“very much” scale to a 0–3 numeric 
scale, each individual was attributed a summary statistic for the sensory subscale (Cronbach 
α = 0.88) and the motor subscale (α = 0.78) by taking the mean of the responses in the 
subscale: none (0; mean = 0), a little (1; 0 < mean ≤ 1), quite a bit (2; 1 < mean ≤ 2), very 
much (3; 2 < mean ≤ 3). Inset: Percent of patients in each group (top of column lists actual 
number of patients) with groups 2 and 3 combined due to low frequency.
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Figure 2. Relationship between weight gain and self-reported health, and severity of CisIPN
Barplots of CisIPN vs A. Weight gain (measured as the BMI difference between evaluation 
and therapy) and B. Self-reported health. BMI difference positively correlated with CisIPN 
(OR = 1.05) after adjusting for age (p = 0.009) or number of years since treatment (p = 
0.004). Self-reported health (poor-excellent) strongly negatively correlated with CisIPN (OR 
= 0.56, p = 2.6 × 10−9), but not with age.
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Figure 3. Genome-wide PrediXcan analysis of CisIPN in TCS
Manhattan and Q-Q plots of associations with PrediXcan expressions in 3 out of 4 candidate 
tissues tested, including A. GTEx skin – not exposed to sun, B. GTEx tibial nerve, C. DGN 
whole blood. Genes that passed the following criteria were included: prediction R2 > 0.01, 
prediction p < 0.05, predicted expression variance > 0.001. Blue lines indicate significance 
threshold within the tissue, −log10 (0.05/ntissue) where ntissue is the number of genes tested in 
the tissue. The green line indicates experiment-wide significance threshold, −log10 (0.05/
ntotal) where ntotal is the total number of tests performed.
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Figure 4. Association of lower RPRD1B expression and CisIPN
Box and cumulative incidence plots of PrediXcan-predicted RPRD1B expression by 
neuropathy status reveal that lower expression correlates with neuropathy in A. The 
Platinum Study’s TCS cohort (p = 3.6 × 10−6), and B. Vanderbilt’s BioVU cohort (one tailed 
p = 0.021) and C. the CALGB 90401 docetaxel trial (one tailed p = 0.055). In plots A and B: 
The centers of the boxplots indicate means, the hinges indicate interquartile regions (IQR), 
the whiskers indicate points within 1.5 × IQR. Data beyond the end of the whiskers are 
outliers plotted as points. In plot B: Logistic regression was performed in BioVU to assess 
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the association between PrediXcan expression and the code for polyneuropathy due to drugs 
– 1 for cases (n = 20), 0 for controls (n = 18,600). In plot C: Cox proportional hazards 
regression was performed to assess the association between PrediXcan expression and a 
dose-to-grade 3 or higher neuropathy event in the CALGB. An arbitrary cutoff is used to 
illustrate the association between the continuous gene expression variable and the dose-to-
event phenotype: Individuals were ranked according to gene expression as determined by 
PrediXcan and the 1st quartile refers to the 25% with the lowest genetically determined 
RPRD1B expression and 2nd to 4th refers to the remaining individuals. Replication was 
assessed by Fisher’s combined p-value of both replications (BioVu and CALGB) and met 
significance (p = 0.0089).
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Table 1
Demographic features and clinical characteristics of 680 genetically European male germ cell tumor (GCT) 
survivors at the time of clinical evaluation
Characteristic Number (%)
Total patients 680
  Age at clinical evaluation (years)
  Median (range) 38 (18–68)
    <20 y 5 (0.7%)
    20–29 y 124 (18.2%)
    30–39 y 251 (36.9%)
    40–49 y 186 (27.4%)
    ≥50 y 114 (16.8%)
  Self-reported race
    White 660 (97.1%)
    Non-white 20 (2.9%)
  Chemotherapy regimen
  Cisplatin, bleomycin, etoposide: totala 428 (62.9%)
    ≤2 cycles 13 (1.9%)
    3 cycles 282 (41.5%)
    4 cycles 124 (18.2%)
    ≥5 cycles 9 (1.3%)
  Cisplatin, etoposide: totalb 203 (29.9%)
    ≤3 cycles 2 (0.3%)
    4 cycles 196 (28.8%)
    ≥5 cycles 5 (0.7%)
  Other cisplatin-based regimen: totalc 49 (7.2%)
    3 cycles 6 (0.9%)
    4 cycles 39 (5.7%)
    ≥5 cycles 4 (0.6%)
  Cumulative dose of cisplatin (mg/m2), all patientsd
    <300 36 (5.3%)
    300 258 (37.9%)
    301–399 28 (4.1%)
    400 328 (48.2%)
    >400 30 (4.4%)
  Time from completion of chemotherapy to clinical evaluation, (years)
    Median (range) 4.8 (0.4–29.9)
    <2 146 (21.5%)
    2–5 250 (36.8%)
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Characteristic Number (%)
    6–9 127 (18.7%)
    ≥10 156 (22.9%)
    Not available 1 (0.1%)
  Hypertension and on prescription medicatione
    Yes 87 (12.8%)
    Nof 593 (87.2%)
  Diabetes and on prescription medicationg
    Yes 21 (3.1%)
    Noh 659 (96.9%)
  Hypercholesterolemia and on prescription medicationi
    Yes 75 (11.0%)
    Noj 605 (89.0%)
  Smoking status
    Current smoker 51 (7.5%)
    Former smoker 234 (34.4%)
    Never smoker 395 (58.1%)
  Average number of alcoholic drinks in past year
    <2 drinks per day 593 (87.2 %)
    ≥2 drinks per day 84 (12.4 %)
    Not indicated 3 (0.4%)
  Self-rating of healthk
    Excellent 114 (16.8%)
    Very good 286 (42.1%)
    Good 249 (36.6%)
    Poor/Fairl 30 (4.4%)
a
Median cumulative cisplatin dose for BEP-treated patients was 300 mg/m2 (range: 200–800): 300 mg/m2 (range: 272–400) among those 
receiving 3 cycles, and 400mg/m2 (range: 344–653) among those receiving 4 cycles. 317 received the standard doses for each cycle (i.e., 
bleomycin 30 units IV weekly, etoposide 100 mg/m2 IV daily × 5 days, cisplatin 20 mg/m2 IV daily × 5 days) and 111 received a modified dose 
for at least one cycle.
b
Median cumulative cisplatin dose for EP-treated patients was 400 mg/m2 among patients receiving 4 cycles (range: 400–600), and among all 
patients (range: 200 – 600). Of patients receiving EP, 129 received standard dose (etoposide 100 mg/m2 IV daily × 5 days, cisplatin 20 mg/m2 IV 
daily × 5 days) and 74 received a modified dose for at least one cycle.
c
Of 49 patients, 24 received cisplatin, etoposide, ifosfamide regimen (17 standard, 7 modified), 14 received combination chemotherapy consisting 
of cisplatin and ifosfamide; 3 received cisplatin, bleomycin, etoposide, and ifosfamide, 1 patient received VelP, 1 patient received PVB, and 1 
patient received unknown cisplatin-based regimen. For the remaining 5 patients, other combinations of cisplatin-based chemotherapy were applied.
d
Median cumulative dose of cisplatin among all patients was 400 mg/m2 (range: 200–800).
e
Includes patients who answered “Yes” to 1) have you ever been diagnosed with high blood pressure and “Yes, current” to 2) have you ever taken 
prescription medications for high blood pressure (including current use).
f
Includes 5 patients for whom status of either hypertension diagnosis or current prescription medication use was not reported.
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g
Includes patients who answered “yes” to either of the following questions: 1) diabetes requiring insulin or 2) diabetes requiring tablets or pills.
h
Includes 13 patients for whom status of diabetes and current prescription medication use was not reported.
i
Includes patients who answered “yes, current” to the following question: have you ever taken prescription medications for high cholesterol.
j
Includes 3 patients for whom status of hypercholesterolemia and on prescription medication use was not reported.
k
Self-rating of health was not indicated by one patient.
l
Out of 30 patients, 25 assigned fair and 5 assigned poor to their self-rating of health.
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Table 2
Association of treatment and other variables with cisplatin-induced peripheral neuropathy. Bolded variables 
are significantly associated at α = 0.05.
  A. Treatment Variables
Model Variable OR (95% CI) P-value
CisIPN ~ Variable Age at diagnosis 1.06 (1.05–1.07) 2 × 10−9
CisIPN ~ Variable (+Agediagnosis) BMI at treatment 1.00 (0.97–1.03) 0.96
Cisplatin dosea (mg/m2) 1.00 (0.99–1.00) 0.39
  B. Variables at Clinical Evaluation
CisIPN ~ Variable Age at evaluation 1.04 (1.03–1.06) 2 × 10−8
CisIPN ~ Variable (+Agediagnosis) Smokingb 1.54 (1.15–2.07) 0.004
Excess drinkingc 1.83 (1.18–2.84) 0.007
Hypertensiond 1.61 (1.04–2.50) 0.03
BMI at evaluation 1.03 (1.00–1.05) 0.051
Diabetese 1.27 (0.54–2.95) 0.59
Hypercholesterolemiaf 0.92 (0.57–1.48) 0.72
  C. Multivariate model
CisIPN ~ Significant Variables Agediagnosis 1.04 (1.02–1.06) 3 × 10−6
Excess drinking 1.82 (1.16–2.86) 0.009
Smoking 1.56 (1.15–2.10) 0.004
Hypertension 1.54 (0.97–2.42) 0.065
a
Dose group was an ordinal variable created from cumulative cisplatin doses (in mg/m2) classified as follows: <300, 300–400 (excluding 400), 
400–500 (excluding 500), and ≥500. OR is based on ordinal group.
b
Includes patients who answered yes to the question “have you ever smoked cigarettes?”
c
Includes patients who answered answered ≥ 2 drinks/day to the question “during the past year, how many drinks of alcoholic beverage have you 
consumed?”
d
Includes patients who answered yes to both of the following: 1) “have you ever been diagnosed with high blood pressure?” and 2) “are you 
currently taking prescription medication for high blood pressure?”
e
Includes those patients who answered “yes” to either of the following questions: 1) “diabetes requiring insulin?” or 2) “diabetes requiring tablets 
or pills?”.
f
Includes those patients who are currently taking prescription medications for high cholesterol.
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